Wells Fargo analyst Larry Biegelsen downgraded Novocure to Equal Weight from Overweight with a price target of $107, up from $89. The analyst says his positive thesis on the shares has played out. The shares have rallied since the positive results from Novocure’s LUNAR lung-cancer study, which is a "huge win" and should bode well for the company’s longer-term outlook, Biegelsen tells investors in a research note. However, in the near-term, debate on the details of the trial and commercial uptake may limit any further share gains, says the analyst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVCR:
- Novocure price target raised to $140 from $100 at H.C. Wainwright
- NVCR, ZLAB Skyrocket as NSCLC Study Meets Primary Endpoint
- Zai Lab, Novocure announces LUNAR study met primary overall survival endpoint
- Novocure announces LUNAR study met primary endpoint
- Novocure added to ‘TAP Underperform’ list at Evercore ISI